FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force

Epilepsia Open. 2021 Feb 25;6(1):45-48. doi: 10.1002/epi4.12475. eCollection 2021 Mar.
No abstract available

MeSH terms

  • Advisory Committees*
  • Anticonvulsants / adverse effects*
  • Anticonvulsants / pharmacology*
  • Epilepsy / drug therapy
  • Heart Disease Risk Factors*
  • Humans
  • Lamotrigine / adverse effects*
  • Lamotrigine / pharmacology*
  • Patient Safety
  • United States
  • United States Food and Drug Administration*

Substances

  • Anticonvulsants
  • Lamotrigine